MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012
This article was originally published in The Gray Sheet
MetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.
You may also be interested in...
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.